Literature DB >> 22460682

Lower-eyelid tarsal ectropion repair with the Putterman ptosis clamp for lower-eyelid conjunctival Mueller's muscle resection and lateral tendon tuck.

Ramesh M Singa1, Vinay K Aakalu, Allen M Putterman, Gil A Epstein.   

Abstract

PURPOSE: To describe a technique for treatment of lower-eyelid tarsal ectropion using the Putterman ptosis clamp for excision of conjunctiva and Mueller's muscle as an adjunct to the lateral canthal tendon tuck.
METHODS: Retrospective case series. Patients with moderate-to-severe lower-eyelid ectropion underwent lateral canthal tendon tucking followed by eversion of the lower eyelid over a desmarres retractor, separation of the lower-eyelid conjunctiva and Mueller's muscle from the underlying capsulopalpebral fascia, placement of the Putterman ptosis clamp, and resection of the incarcerated tissue followed by closure of the conjunctiva and the lateral canthus.
RESULTS: Six patients and 8 eyes were studied. Of the 8 eyes, 6 (75%) had complete resolution of tarsal ectropion and 2 (25%) had mild residual ectropion at last follow up. All 8 eyes (100%) had symptomatic improvement and 0 patients required re-operation. There were no noted severe adverse events.
CONCLUSION: Lower-eyelid conjunctival Mueller's muscle resection using the Putterman ptosis clamp as an adjunct to lateral canthal tendon reinforcement is a safe and effective procedure in the treatment of lower-eyelid tarsal ectropion.

Entities:  

Mesh:

Year:  2012        PMID: 22460682     DOI: 10.1097/IOP.0b013e31824a4b0c

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  2 in total

1.  Re: "Lower eyelid involutional ectropion repair with lateral tarsal strip and internal retractor reattachment with full-thickness eyelid sutures".

Authors:  Gil Epstein; Vinay K Aakalu; Allen M Putterman
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 May-Jun       Impact factor: 1.746

Review 2.  Involutional ectropion: etiological factors and therapeutic management.

Authors:  Abdulaziz S AlHarthi
Journal:  Int Ophthalmol       Date:  2022-09-02       Impact factor: 2.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.